The registrational trial missed its core efficacy test. LEVEL failed to achieve statistical significance on both the primary 6-minute walk endpoint and the key KCCQ symptom-score endpoint, the outcomes most directly needed to support approval. The overall 6MWD difference was only 3.5 meters with p=0.63, while the quality-of-life difference was 0.1 points. Against the trial’s approval-oriented objective, this is a clear miss. (Key Results from LEVEL)
| Measure | TNX-103 | Placebo | Difference / result |
|---|---|---|---|
| 6MWD change at Week 12 | +14.0 m | +10.4 m | +3.5 m; p=0.63 — primary endpoint not met (Key Results from LEVEL) |
| KCCQ-TSS change at Week 12 | +6.6 | +6.5 | +0.1 points — key secondary endpoint not met (Key Results from LEVEL) |
| NT-proBNP change from baseline | -39.1 pmol/L | +13.7 pmol/L | 49% placebo-adjusted reduction; nominal p<0.0001 (Prespecified Exploratory Biomarker and Hemodynamic Analyses) |
| RVSP | — | — | 3.5 mmHg placebo-controlled reduction; nominal p=0.0045 (Prespecified Exploratory Biomarker and Hemodynamic Analyses) |
| Adverse events | 86.7% | 71.9% | Higher with TNX-103 (Safety) |
| Serious adverse events | 10.8% | 10.7% | Balanced between arms (Safety) |
The positive signal is concentrated in a narrower, sicker subgroup rather than the enrolled population as a whole. Patients below the median baseline walking distance of 333 meters improved 26.3 meters versus placebo, with a nominal p=0.0112; the oldest patients showed similarly large effects. That is clinically relevant, but it is a prespecified subgroup result, not success on the overall primary endpoint, and the company explicitly notes that nominal p-values were not adjusted for multiplicity. (Prespecified Analyses of Primary Endpoint)
The biomarker and hemodynamic data preserve biological credibility but do not replace the failed clinical endpoints. A 49% reduction in NT-proBNP and a 3.5 mmHg reduction in RVSP suggest TNX-103 is affecting cardiac stress and pulmonary pressure across the overall population. However, these were exploratory endpoints, and the filing does not establish that they translate into improved symptoms, exercise capacity, or outcomes sufficient for approval. (Prespecified Exploratory Biomarker and Hemodynamic Analyses)
The regulatory path has shifted from execution to negotiation. Tenax plans to request an FDA Type C meeting and propose enriching a future development population around patients with greater disease burden. That keeps the program alive, but it also means the current trial did not deliver the clean, broad efficacy result investors would have wanted from a registrational Phase 3 study. The FDA’s prior willingness to consider one Phase 3 trial with a p-value of 0.01 may help, but the company still needs FDA agreement that the subgroup-driven strategy can support an NDA. (Conference Call and Webcast)
Safety was acceptable on serious events but not a clean win overall. Serious adverse events were essentially identical between arms, and no new safety signal was reported. Still, overall adverse events and treatment-related adverse events were materially more frequent with TNX-103, limiting how strongly the safety profile offsets the efficacy miss. (Safety)
Net read: materially worse than the approval-oriented expectation, with subgroup data offering a salvage route rather than a victory. The filing turns TNX-103 from a potentially straightforward Phase 3 success into a program dependent on regulatory feedback, population enrichment, and confirmation that the lower-functioning subgroup is the right target. No external published consensus was provided; versus the trial’s own registrational bar, the primary readout is a significant miss despite encouraging mechanistic signals.
Read the original 8-K on SEC EDGAR ↗